Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Albireo Pharma Inc (NASDAQ:ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of A3907 in adult liver disease.
- Data will be presented at the EASL International Liver Congress 2021.
- Results in children with familial intrahepatic cholestasis (PFIC) from two Phase 3 studies showed that Bylvay was associated with rapid reductions in serum bile acid levels and improved pruritus severity, with durable clinical benefits sustained through 48 weeks of treatment.
- The observed safety and tolerability profile of Bylvay was consistent across studies, treatment groups, and doses. No drug-related serious adverse events were reported.
- One patient in PEDFIC 1 and 3 patients in PEDFIC 2 treated with Bylvay withdrew due to an adverse event.
- There were low gastrointestinal adverse events; treatment-related diarrhea/frequent bowel movements were reported in 10% of Bylvay treated patients in PEDFIC 1 and 5% of placebo-treated patients.
- Patients with PFIC who responded to Bylvay treatment had sustained improvements in cholestasis-related parameters over 48 weeks that were not observed to the same extent in treatment non-responders.
- The Company will also have a presentation and poster on Phase 1 candidate, A3907, with preclinical data showing efficacy on markers of cholestatic disease.
- Price Action: ALBO shares are up 2.21% at $35.03 during the market trading session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!